Cyclo Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Cyclo Therapeutics files an amendment to its annual report, detailing a recent merger, clinical trial updates, and financial results for the year ended December 31, 2023.
Cyclo Therapeutics has filed an amendment to its 2023 annual report to address SEC comments and provide additional details regarding its merger with Applied Molecular Transport, Inc.
Cyclo Therapeutics has filed an amendment to its annual report to include previously omitted information regarding principal accountant fees and services.
Cyclo Therapeutics, Inc.'s annual 10-K filing provides a detailed overview of the company's securities, including common stock and warrants, as well as anti-takeover provisions and recent business activities.